Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

Nov 4 2009

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad^® at the 47^th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1^st).

The additional results from BioAlliance Pharma’s pivotal Phase III study with miconazole Lauriad^® mucoadhesive buccal tablets (MBT) demonstrated comparable efficacy and safety profile to that of clotrimazole troches (administered five times per day) for oropharyngeal candidiasis (OPC), in HIV-positive patients in 40 sites in the United States, Canada and South Africa. The data also demonstrated a good patient compliance as a result of the added convenience of a once-a-day dosing.

This presentation was given by Dr Rajesh V. Lalla, oral medicine specialist, from the University of Connecticut Health Center.

OPC, also known as thrush, is an oral fungal infection most common in individuals with weakened immune systems – particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.